{
    "name": "tralokinumab",
    "comment": "Rx",
    "other_names": [
        "Adbry",
        "tralokinumab-ldrm"
    ],
    "classes": [
        "Interleukin Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/adbry-tralokinumab-4000121",
    "pregnancy": {
        "common": [
            "Limited data are available on use in pregnant females ",
            "Human IgG antibodies are known to cross placental barrier; therefore, drug may be transmitted from mother to developing fetus"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "In an enhanced prenatal and postnatal developmental study, no adverse developmental effects were observed in offspring born to pregnant monkeys after IV tralokinumab during organogenesis through parturition at doses up to 10x the maximum recommended human dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on drug presence in human milk, effects on breastfed infants, or effects on milk production",
            "Maternal IgG is present in breast milk",
            "Effects of local gastrointestinal exposure and limited systemic exposure on breastfed infants are unknown"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to tralokinumab or any excipients in drug product"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reaction, including anaphylaxis and angioedema, have occurred; discontinue therapy if hypersensitivity reaction occurs",
                "Conjunctivitis and keratitis reported; report new onset or worsening eye symptoms to healthcare provider",
                "Treat patients with pre-existing helminth infections before initiating; if infection develops during treatment and is unresponsive to antihelminth therapy, discontinue treatment until infection resolves"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Vaccinations",
                        "Avoid use of live vaccines",
                        "Tralokinumab may alter immunity and increase the risk of infection following administration of live vaccines",
                        "Limited data are available regarding coadministration with non-live vaccines"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "tralokinumab decreases effects of adenovirus types 4 and 7 live, oral by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "tralokinumab, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "tralokinumab decreases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "tralokinumab, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "tralokinumab, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "tralokinumab decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "tralokinumab, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "tralokinumab decreases effects of influenza virus vaccine quadrivalent, intranasal by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "tralokinumab, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "tralokinumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "tralokinumab decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "tralokinumab decreases effects of rotavirus oral vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "tralokinumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "tralokinumab, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "tralokinumab decreases effects of typhoid vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "tralokinumab decreases effects of varicella virus vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "tralokinumab decreases effects of yellow fever vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "tralokinumab decreases effects of zoster vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid use of live vaccines. Before starting tralokinumab, complete age appropriate immunizations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anthrax vaccine adsorbed",
            "description": {
                "common": "tralokinumab will decrease the level or effect of anthrax vaccine adsorbed by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "COVID-19 vaccine, adjuvanted-Novavax",
            "description": {
                "common": "tralokinumab will decrease the level or effect of COVID-19 vaccine, adjuvanted-Novavax by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "COVID-19 vaccine, mRNA-Pfizer",
            "description": {
                "common": "tralokinumab will decrease the level or effect of COVID-19 vaccine, mRNA-Pfizer by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "COVID-19 vaccine, viral vector-Janssen",
            "description": {
                "common": "tralokinumab will decrease the level or effect of COVID-19 vaccine, viral vector-Janssen by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haemophilus influenzae type b vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of haemophilus influenzae type b vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis A vaccine inactivated",
            "description": {
                "common": "tralokinumab will decrease the level or effect of hepatitis A vaccine inactivated by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis a/b vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of hepatitis a/b vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hepatitis b vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of hepatitis b vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "HIV vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of HIV vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "human papillomavirus vaccine, bivalent",
            "description": {
                "common": "tralokinumab will decrease the level or effect of human papillomavirus vaccine, bivalent by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "human papillomavirus vaccine, nonavalent",
            "description": {
                "common": "tralokinumab will decrease the level or effect of human papillomavirus vaccine, nonavalent by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "human papillomavirus vaccine, quadrivalent",
            "description": {
                "common": "tralokinumab will decrease the level or effect of human papillomavirus vaccine, quadrivalent by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza A (H5N1) vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of influenza A (H5N1) vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine (H5N1), adjuvanted",
            "description": {
                "common": "tralokinumab will decrease the level or effect of influenza virus vaccine (H5N1), adjuvanted by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent",
            "description": {
                "common": "tralokinumab will decrease the level or effect of influenza virus vaccine quadrivalent by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "tralokinumab will decrease the level or effect of influenza virus vaccine quadrivalent, adjuvanted by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, cell-cultured",
            "description": {
                "common": "tralokinumab will decrease the level or effect of influenza virus vaccine quadrivalent, cell-cultured by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, recombinant",
            "description": {
                "common": "tralokinumab will decrease the level or effect of influenza virus vaccine quadrivalent, recombinant by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent",
            "description": {
                "common": "tralokinumab will decrease the level or effect of influenza virus vaccine trivalent by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "tralokinumab will decrease the level or effect of influenza virus vaccine trivalent, adjuvanted by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent, recombinant",
            "description": {
                "common": "tralokinumab will decrease the level or effect of influenza virus vaccine trivalent, recombinant by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "Japanese encephalitis virus vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of Japanese encephalitis virus vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal A C Y and W-135 diphtheria conjugate vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of meningococcal A C Y and W-135 diphtheria conjugate vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal A C Y and W-135 polysaccharide vaccine combined",
            "description": {
                "common": "tralokinumab will decrease the level or effect of meningococcal A C Y and W-135 polysaccharide vaccine combined by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal C and Y/haemophilus influenza type B vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of meningococcal C and Y/haemophilus influenza type B vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal group B vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of meningococcal group B vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pneumococcal vaccine 13-valent",
            "description": {
                "common": "tralokinumab will decrease the level or effect of pneumococcal vaccine 13-valent by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pneumococcal vaccine 15-valent",
            "description": {
                "common": "tralokinumab will decrease the level or effect of pneumococcal vaccine 15-valent by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pneumococcal vaccine 20-valent",
            "description": {
                "common": "tralokinumab will decrease the level or effect of pneumococcal vaccine 20-valent by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pneumococcal vaccine heptavalent",
            "description": {
                "common": "tralokinumab will decrease the level or effect of pneumococcal vaccine heptavalent by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pneumococcal vaccine polyvalent",
            "description": {
                "common": "tralokinumab will decrease the level or effect of pneumococcal vaccine polyvalent by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "poliovirus vaccine inactivated",
            "description": {
                "common": "tralokinumab will decrease the level or effect of poliovirus vaccine inactivated by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of rabies vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rabies vaccine chick embryo cell derived",
            "description": {
                "common": "tralokinumab will decrease the level or effect of rabies vaccine chick embryo cell derived by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "SARS-CoV-2 vaccine, inactivated",
            "description": {
                "common": "tralokinumab will decrease the level or effect of SARS-CoV-2 vaccine, inactivated by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetanus toxoid adsorbed or fluid",
            "description": {
                "common": "tralokinumab will decrease the level or effect of tetanus toxoid adsorbed or fluid by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tick-borne encephalitis vaccine",
            "description": {
                "common": "tralokinumab will decrease the level or effect of tick-borne encephalitis vaccine by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine recombinant",
            "description": {
                "common": "tralokinumab will decrease the level or effect of zoster vaccine recombinant by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Upper respiratory tract infections",
            "percent": "23.8"
        },
        {
            "name": "Upper respiratory tract infections",
            "percent": "30"
        },
        {
            "name": "Conjunctivitis",
            "percent": "13.6"
        },
        {
            "name": "Injection site reactions",
            "percent": "11.1"
        },
        {
            "name": "Conjunctivitis",
            "percent": "7.5"
        },
        {
            "name": "Injection site reactions",
            "percent": "7.4"
        },
        {
            "name": "Eosinophilia",
            "percent": "1.4"
        },
        {
            "name": "Eosinophilia",
            "percent": "1.2"
        }
    ]
}